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license (http://creativecommons.org/Abstract Although statins have been used for the treatment of hypercholesterolemia for
more than two decades, cardiovascular disease (CVD), which is related at least in part to high
levels of low-density lipoprotein cholesterol (LDL-C), is the number one cause of death in Eur-
ope and the USA. Several studies have shown that the reduction in cardiovascular (CV) events is
proportional to the absolute LDL-C lowering achieved with statins. In the quest for further
reduction in LDL-C and CV events, new drugs that mainly support statin action have emerged.
Since 2003, with the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9), which
is a key factor in the LDL clearance pathway, new modalities, mainly in the form of monoclonal
antibodies that block this protein (PCSK9 inhibitors), have reached phase III of clinical devel-
opment with very promising efficacy and safety data. With a mean further reduction of LDL-C
levels ofw60% beyond that achieved with statins, the PCSK9 inhibitors set the bar even lower
in terms of LDL-C levels. This review manuscript addresses important questions about the ef-
ficacy, safety and clinical use of PCSK9 inhibitors to evaluate the role of these agents in
reducing CV risk.
ª 2016 Hellenic Cardiological Society. Publishing services by Elsevier B.V. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Cardiovascular disease (CVD) is the leading cause of death
in Europe and the USA.1,2 Over the past few years, studiesRallidis, 74 Thermopylon,
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y of Hellenic Cardiological
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cal Society. Publishing services by
licenses/by-nc-nd/4.0/).have shown a very strong correlation between low-density
lipoprotein cholesterol (LDL-C) levels and the develop-
ment of CVD, mainly due to the key role of LDL-C in the
atherosclerotic process.3,4 The treatment of hypercholes-
terolemia has been primarily based on statin use. Indeed,
statins have successfully served their purpose as a very
effective lipid lowering medication class for 25 years since
their introduction. However, a significant number of very
high risk patients fail to achieve the LDL-C targets despite
statin treatment necessitating the development of new
agents for additional LDL-C lowering.5Elsevier B.V. This is an open access article under the CC BY-NC-ND
PCSK9 inhibition as an emerging lipid therapy 87Following the discovery of the LDL receptor (LDLR) by
Goldstein and Brown,6 a new part of the puzzle of LDL
clearance and homeostasis was elucidated by Abifadel and
her coworkers in 2003.7 The discovery of proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) by this group not
only identified a new important and unknown element of
the LDL clearance mechanism but also explained the limi-
tations of statin therapy. PCSK9 is the last identified
member of the proprotein convertase family. It is produced
mainly in hepatocytes, and after an auto-processing
cleavage reaction, it is secreted in the plasma where it
binds with the LDLR. This does not interfere with the LDLR’s
ability to bind with LDL, but it incapacitates the LDLR’s
ability to return to the surface of the hepatocyte and bind
to a new LDL molecule (Fig. 1). In particular, the direct
interaction between PCSK9 and LDLR leads to the destruc-
tion of the receptors, a decrease in their concentration at
the surface of the hepatocytes and a reduction in LDL
clearance from the plasma. An important aspect of this
process is that at the transcriptional level, PCSK9 produc-
tion is upregulated by the activity of sterol regulatory
element binding protein-2 (SREBP-2). SREBP-2 activity is
increased in very low levels of intracellular cholesterol in
the hepatocytes, and its main role is to promote the tran-
scription of LDLR and PCSK9. As statins diminish intracel-
lular cholesterol synthesis, they indirectly promote both
LDLR and PCSK9 production through SREBP-2. This explains
the statin treatment plateau that is achieved even at
maximal doses.8 Although PCSK9 was initially discovered
through the analysis of familial hypercholesterolemia (FH)
patients with a gain of function (GOF) mutation of the
PCSK9 gene, further studies have revealed naturally
occurring loss of function (LOF) mutations. Homozygotes or
compound heterozygotes for two LOF mutations in the
PCSK9 gene have minimal or even no PCSK9 production;
their LDL-C levels are 20 mg/dL, and they are healthy.9
These findings, in conjunction with the extracellular
PCSK9 mode of action and the identification of its crystal
structure and its active binding site with the LDLR,10,11 have
led to the development of pharmaceutical agents aimed at
PCSK9 inhibition. To date, one of these modalities has been
extensively tested and reached phase III of clinical devel-
opment with great success. The use of monoclonal anti-
bodies (mAbs) as a means of inhibiting PCSK9 action hasFigure 1 Left panel: LDL receptors carry LDL particles into hepa
allowing the recycling of LDL receptors to the cell membrane up to
type 9 (PCSK9) binds to LDL receptors, and the complex LDL recep
plasma concentrations of PCSK9 result in low levels of LDL recept
cholesterol.shown consistent efficacy regarding the reduction of LDL-C
levels (w60%) and a good safety profile with short-term
administration.
To date, two of these fully human mAbs (evolocumab
developed by Amgen and alirocumab developed by Sanofi/
Regeneron) have completed most of their phase III pro-
grams, whereas a third PCSK9 inhibitor, bococizumab
developed by PFIZER, is currently in phase III trials. On July
21st, 2015 and August 27th, 2015, the European Commission
(EC) and the US Food and Drug Administration (FDA),
respectively, announced the approval of evolocumab
(Repatha) as an adjunct to diet and maximally tolerated
statin therapy in adult patients with FH who failed to
achieve LDL-C treatment goals, adult patients who were
unable to tolerate statin therapy, and in homozygous FH
adults and adolescents (12 years old). On July 25th, 2015,
the FDA, and one month later the EC, approved alirocumab
(Praluent) as an adjunct to diet and maximally tolerated
statin therapy for the treatment of adults with heterozy-
gous FH or CVD, who require additional lowering of LDL-C
and in patients who cannot tolerate statins.
Recently, a reduction of cardiovascular (CV) events with
the administration of PCSK9 inhibitors was reported. In the
ODYSSEY LONG TERM trial, 2341 high-risk patients with LDL-
C levels 70 mg/dL while on a maximally tolerated statin
dose were randomized in a 2:1 ratio to 150 mg alirocumab
every two weeks subcutaneously or placebo over a period
of 78 weeks. Alirocumab reduced LDL-C levels by an addi-
tional 62%, and post hoc analysis showed that this was
associated with a 48% relative risk reduction of CV events
(1.7% in the alirocumab group vs. 3.3% in the placebo group,
p Z 0.02).12
In addition, the OSLER (Open-Label Study of Long-Term
Evaluation against LDL Cholesterol)-1 and OSLER-2 trials
reported similar results. The participants of the OSLER-1
trial had already completed one of the five phase 2 parent
evolocumab studies, whereas the OSLER-2 participants had
participated in at least one of the seven phase III evolo-
cumab studies.13 Patients (n Z 4465) were randomly
assigned in a 2:1 ratio to receive either subcutaneous
evolocumab 140 mg every two weeks or 420 mg monthly in
addition to their standard therapy or standard therapy
alone. The use of evolocumab plus standard therapy
reduced the levels of LDL-C by 61% compared to standardtocytes via clathrin-coated vesicles that fuse with endosomes
150 times. Right panel: Proprotein convertase subtilisin/kexin
tor-PCSK9 is degraded in the lysosomes. Therefore, increased
ors at the cell surface and increased levels of circulating LDL
88 L.S. Rallidis, J. Lekakistherapy alone and reduced the incidence of CV events by
53% in a prespecified exploratory analysis. In particular, the
rate of CV events at one year was reduced from 2.18% in the
standard therapy group to 0.95% in the evolocumab plus
standard therapy group (p Z 0.003).
Although these results are encouraging, it should be
emphasized that the number of CV events was relatively
low and the duration of follow-up was short for a treatment
of a chronic disease. Before this novel lipid lowering
treatment takes its place among the other hypolipidemics,
several questions should be addressed:
1) How safe is the chronic exposure to monoclonal
antibodies?
The viability of PCSK9 inhibition with mAbs in clinical
practice is highly dependent on their safety profile. The
chronic exposure to mAbs raises some concerns regarding
mild hypersensitivity reactions and immune responses. The
fact that evolocumab and alirocumab are fully human mAbs
minimizes the possibility of such reactions but may not
completely eliminate the risk. This is because several other
factors that are unrelated to the primary sequence may
contribute to the immunogenic potential, such as aggre-
gation of mAbs induced upon storage, protein conforma-
tion, impurities arising from the production method, etc.14
It should be noted here that real-life data regarding the use
of mAbs for rheumatoid arthritis and Crohn’s disease have
shown that they are well tolerated over the long-term.15
2) How safe are the very low LDL-C levels achieved by
the combination of PCSK9 inhibitors with statins?
The safety issue of low LDL-C levels has been raised
since the publication of the first randomized studies with
intensive statin therapy where LDL-C levels beyond the
target had been achieved.16,17 This concern is justified by
the fact that cholesterol is an essential component of
cellular membranes and neurons and is also necessary for
steroid hormones and vitamin D synthesis. However, LDL-C
levels in the range of 40 to 50 mg/dL that currently seem
very low are possibly the genetically determined “ideal”
LDL-C levels for humans. This is based on the fact that LDL-
C levels are w40 mg/dL in healthy neonates and 50 to
75 mg/dL in hunter/gatherer populations (e.g., Pygmies)
that continue to live primitively and in whom coronary
atherosclerosis is rare or non-existent.18 Hence, the issue is
whether very low LDL-C levels achieved by hypolipidemic
agents are safe.
The answer to this question is not straightforward
because only few data exist regarding the safety of very low
levels of LDL-C as achieved with intensive lipid lowering
therapy.
Subgroup analysis of the PROVE IT-TIMI 22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22) trial according
to achieved LDL-C levels while on statin treatment has
shown that patients with very low LDL-C levels (<40 mg/dL)
had a similar safety profile compared with those with LDL-C
levels 40 mg/dL, and there was no case of rhabdomyolysis
or brain haemorrhage.19 However, only a limited number ofpatients (n Z 193) had LDL-C levels <40 mg/dL, and the
follow-up period was only two years.
A post hoc analysis of 16,304 participants enrolled in the
JUPITER (Justification for the Use of Statins in Prevention:
An Intervention Trial Evaluating Rosuvastatin) trial raised
some concerns regarding the safety of very low LDL-C levels
achieved by the administration of 20 mg rosuvastatin
daily.20 In particular, 767 patients who had LDL-C levels
<30 mg/dL, despite the clinical benefits, showed an in-
crease in the rates of physician-reported diabetes mellitus,
haematuria, hepatobiliary disorders, and insomnia
compared with participants taking rosuvastatin who had
LDL-C levels 30 mg/dL.
When a PCSK9 inhibitor is added to statin therapy, very
low LDL-C levels are expected in a significant proportion of
patients whose initial LDL-C levels are in the range of 70 to
100 mg/dL. This was shown in the LAPLACE-2 (LDL-C
Assessment with PCSK9 Monoclonal Antibody Inhibition
Combined with Statin Therapy) trial where evolocumab
added to moderate or high-intensity statin therapy and
compared with ezetimibe or placebo in hypercholesterol-
emic patients for 12 weeks resulted in very low LDL-C
levels.21 Particularly, w20% of the moderate-intensity
statin group and w40% of the high-intensity statin group
achieved LDL-C levels <25 mg/dL. Despite these very low
LDL-C levels, adverse events occurred at similar pro-
portions in the three studied groups i.e., in 36% of
evolocumab-treated patients, 40% of ezetimibe-treated
patients, and 39% of placebo-treated patients.
The OSLER studies also suggested no significant adverse
effects of intensive LDL-C lowering.13 After approximately
one year of therapy, the risk of adverse events, including
neurocognitive events, did not vary significantly across
subgroups formed by achieved LDL-C levels, i.e., LDL-C
<25 mg/dL, LDL-C between 25 and <40 mg/dL, and LDL-C
40 mg/dL compared to the standard of care alone arm.
Efficacy and safety data regarding the administration of
alirocumab were also reported by the COMBO II study.22
This was a double-blind, active-controlled, parallel-group,
104-week study of alirocumab vs. ezetimibe. In particular,
720 patients with high CV risk and elevated LDL-C levels
despite maximal doses of statins were randomized with a
2:1 allocation ratio to subcutaneous alirocumab 75 mg
every two weeks (plus oral placebo) or oral ezetimibe 10 mg
daily (plus subcutaneous placebo). At week 24, the mean
reduction in LDL-C from baseline was w51% for the alir-
ocumab group and w21% for the ezetimibe group, and
these reductions remained largely constant up to 52 weeks.
Alirocumab was generally well tolerated with no evidence
of an excess of adverse events. A similar safety profile
showed 105 patients (22.8% of 460) in the alirocumab arm
who had two consecutive LDL-C values <25 mg/dL during
the treatment period.
To date, the side effect profile of PCSK9 inhibitors is
comparable to the placebo group. However, the interven-
tion period is short (3-12 months), and long-term follow-up
is mandatory to prove the safety of PCSK9 inhibition. There
is some reassurance in knowing that the few people who
were compound heterozygotes for two LOF PCSK9 gene
mutations appear to be in good health despite the strikingly
low LDL-C levels (w15 mg/dL).9 However, safety data
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to individuals with genetically normal PCSK9 suppressed by
a pharmaceutical intervention. In addition, the impairment
of neurocognitive function remains a concern with such
drastic reductions in LDL-C levels. Despite the low overall
rate of neurocognitive adverse events in the OSLER (0.9%)
and the ODYSSEY LONG TERM (1.2%) studies, the rate of
self-reported neurocognitive events was slightly higher
than in the placebo groups. The issue of neurocognitive
adverse effects will be addressed by a dedicated neuro-
cognitive substudy of the FOURIER study. This substudy
(Evaluating PCSK9 Binding antiBody Influence oN coGnitive
HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)
(ClinicalTrials.gov Identifier: NCT02207634) will objectively
determine neurocognitive function via neurocognitive
testing.
3) Do PCSK9 inhibitors have effects beyond LDL-C
lowering?
Statins have several CV effects, collectively called
pleiotropic effects, most likely not entirely explained by
LDL-C lowering, such as amelioration of endothelial
dysfunction, halting or retardation of atheroma develop-
ment, antithrombotic effects and the reduction of inflam-
mation and oxidation.23 These effects may, at least partly,
arise from the inhibition of several mevalonate-derived
metabolites, which are involved in the control of various
cellular functions. It has been hypothesized that these
additional effects contribute, at least partly, to the clinical
benefits of statins.
PCSK9 inhibitors have an entirely different mechanism of
action. Because the metabolic pathway of cholesterol
synthesis remains intact, the pleiotropic effects of statins,
which might be related to mevalonate-derived metabolites,
do not appear with PCSK9 inhibition. Conversely, PCSK9
inhibitors show some additional lipid effects, such as the
reduction in lipoprotein (a) [Lp(a)]. In particular, a w30%
reduction in Lp(a) has been reported with the administra-
tion of evolocumab24 or alirocumab.25 Whether this Lp(a)
lowering effect is translated into clinical benefit remains to
be elucidated. In addition, because the exact functional
role of PCSK9 is unknown, it cannot be predicted whether
chronic inhibition of PCSK9 will uncover new off-target ef-
fects with unknown impact on the atherogenic process.
PCSK9 appears to exhibit several metabolic effects that
need to be further explored.26 It has been proposed that
PSCK9 may play roles in neuronal apoptosis, regulation of
sodium channels, nervous system development, septic
pathogen lipid transport and clearance, etc.27,28 In addi-
tion, circulating PCSK9 has been reported to be associated
with plasma glucose, body mass index and blood pressure.29
4) Are lower LDL-C levels better?
Large randomized, outcome trials support a treatment
target of LDL-C levels in very high risk patients of less than
70 mg/dL, as this is associated with improved clinical out-
comes. To date, it is unknown whether there is a threshold
below which patients do not benefit from lower LDL-C
levels. To assess the benefit of even lower LDL-C, it isimportant to recognize that CV risk reduction is not pro-
portional to the percent change but rather to the absolute
reduction in LDL-C levels.30 Therefore, the risk reduction
for the same relative LDL-C lowering diminishes with lower
baseline LDL-C levels.31
A meta-analysis that included 38,153 patients from eight
randomized controlled statin trials showed that patients
achieving an LDL-C level <50 mg/dL were at significantly
lower risk for major CV events compared with those
reaching LDL-C levels of 75 to <100 mg/dL (adjusted hazard
ratio: 0.81; 95% confidence interval: 0.70 to 0.95).32
The recently published IMPROVE-IT (IMProved Reduction
of Outcomes: Vytorin Efficacy International Trial) also re-
inforces “the lower the better” hypothesis.33e35 In that
study, a total of 18,144 patients with a recent acute coro-
nary syndrome and LDL-C levels 125 mg/dL (100 mg/dL
if they had taken previous hypolipidemic medication) were
randomized to either 40 mg simvastatin alone or 40 mg
simvastatin plus 10 mg ezetimibe daily. The mean level of
LDL-C achieved in the simvastatin group was 69.5 mg/dL
compared with 53.7 mg/dL in the combined treatment
group. Thew16 mg/dL reduction of LDL-C achieved by the
addition of ezetimibe to simvastatin was associated with a
further modest clinical benefit, i.e., a 6.4% relative
reduction of all CV events.
Although there are encouraging findings supporting “the
lower the better”, this hypothesis will be confirmed or
rejected when the clinical outcome trials with PCSK9 in-
hibitors (FOURIER [Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated
Risk] and ODYSSEY LONG-TERM trials) will be completed in
w2 years.
5) Which patients are candidates for PCSK9 inhibitors?
The introduction of statins 25 years ago changed the
landscape of lipid lowering therapy. Statins have been
incorporated into all national and international guidelines
for the treatment of hypercholesterolemia in coronary ar-
tery disease (CAD). The benefits of statins have been shown
to be significant, both in the primary and secondary pre-
vention of CAD. Despite the large benefit, a significant
number (w15-20%) of CAD patients on statin treatment still
develop CV events within a five-year period. This may be
due to failure to attain LDL-C goals, to co-existence of
other risk factors, such as diabetes mellitus, Lp(a), and
atherogenic dyslipidaemia, that are not treated sufficiently
with existing drugs, or to the presence of other, as yet
unknown, CAD risk factors .36
Failure to achieve LDL-C levels was shown in the
EUROASPIRE (European Action on Secondary and Primary
Prevention by Intervention to Reduce Events) IV trial,37
which recorded risk factors from 24 European countries in
individuals with established CAD. This survey, conducted
from May 2012 to April 2013, showed that despite the high
reported use of statins in secondary prevention (w86%),
only one of five patients achieved the therapeutic target
for LDL-C, <70 mg/dL. This therapeutic deficit may be due
to inadequate up-titration of the statin dose or the failure
of high dose statins to attain LDL-C goals because of very
high initial LDL-C levels.
Table 1 Potential candidates for PCSK9 inhibitors may include:
1) Patients with CVD and LDL-C 100 mg/dL despite maximal tolerated dose of effective statin (20/40 mg rosuvastatin or 40/
80 mg atorvastatin daily) þ ezetimibe (10 mg daily)
2) Heterozygous FH patients without CVD and LDL-C 130 mg/dL despite maximal tolerated dose of effective statin (20/40 mg
rosuvastatin or 40/80 mg atorvastatin daily) þ ezetimibe (10 mg daily)
3) Diabetic patients without CVD but with 1 cardiovascular risk factors and/or target organ damage and LDL-C 100 mg/dL
despite maximal tolerated dose of effective statin (20/40 mg rosuvastatin or 40/80 mg atorvastatin daily) þ ezetimibe (10 mg
daily)
4) Statin-intolerant patients (documented intolerance to 2 statins) who, despite ezetimibe  bile acid sequestrants use have:
a) LDL-C 100 mg/dL (very high risk patients) or
b) LDL-C 130 mg/dL (high risk patients).
5) Homozygous FH patients aged 12 years in combination with other lipid-lowering therapies (only evolocumab has been
approved).
CVD Z cardiovascular disease, LDL-C Z low density lipoprotein-cholesterol, FH Z familial hypercholesterolemia.
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development of statin-associated muscle symptoms. In
clinical practice, w10% of patients receiving statins
develop muscle symptoms.38,39 The PRIMO (Prediction of
Muscular Risk in Observational conditions) study showed
that 17% of patients on statins with muscular symptoms
decreased the dose of statins, while 20% of them dis-
continued it.40 For those who discontinued the statins, 70%
of them can tolerate lower doses of statins.38
Promising results for treating hypercholesterolemia in
patients who cannot tolerate statins due to muscle symp-
toms yielded the GAUSS-2 (Goal Achievement After Utilizing
an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2)
trial.41 This study selected 307 patients who were intol-
erant to 2 statins due to muscle symptoms and random-
ized them to evolocumab (140 mg every two weeks or
420 mg once monthly) or ezetimibe 10 mg daily for 12
weeks. Muscle adverse events occurred in only 12% of the
evolocumab-treated patients and 23% of the ezetimibe-
treated patients.
Therefore, potential candidates for PCSK9 inhibition
may be high risk or very high risk patients who are unable to
reach the LDL-C target despite treatment with the highest
tolerable statin dose plus ezetimibe or statin-intolerant
patients (very high or high risk). However, taking into ac-
count the fact that long-term CV outcome data are not
available yet and the presumed high cost of these medi-
cations, we currently suggest a more conservative treat-
ment approach (Table 1).42 Applying these criteria, we
estimate that approximately <5% of all very high risk
patients with hypercholesterolemia will be candidates for
PCSK9 inhibitors.
2. Conclusions
The discovery of PCSK9 in 2003 considerably changed the
therapeutic reality in the lipid field. PCSK9 reduces LDLR
recycling and increases LDL-C levels. Fully human mAbs are
currently the most advanced PCSK9 inhibitors. They result in
a consistent decrease in LDL-C levels ofw60%, either on top
of statins or as a monotherapy. Long-term randomized
controlled clinical trials are underway to assess the safety,
tolerability, and efficacy of PCSK9 inhibitors to reduce CV
events. If these trials show positive results, PCSK9 inhibitorswill offer a novel and powerful therapeutic option for pa-
tients with difficult-to-treat hypercholesterolemia.
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